Comprehensive Addiction and Recovery Act of 2016 (CARA) / Medicare Prescription Drug Benefit Program (CMS-10141)

ICR 202003-0938-008

OMB: 0938-0964

Federal Form Document

ICR Details
0938-0964 202003-0938-008
Historical Inactive 201906-0938-001
HHS/CMS CM-CPC
Comprehensive Addiction and Recovery Act of 2016 (CARA) / Medicare Prescription Drug Benefit Program (CMS-10141)
Revision of a currently approved collection   No
Regular
Comment filed on proposed rule and continue 05/14/2020
Retrieve Notice of Action (NOA) 04/30/2020
Terms of the previous clearance remain in effect. OMB files this comment in accordance with 5 CFR 1320.11( c ). This OMB action is not an approval to conduct or sponsor an information collection under the Paperwork Reduction Act of 1995. This action has no effect on any current approvals. If OMB has assigned this ICR a new OMB Control Number, the OMB Control Number will not appear in the active inventory. For future submissions of this information collection, reference the OMB Control Number provided. OMB is withholding approval at this time. Prior to publication of the final rule, the agency should provide a summary of any comments related to the information collection and their response, including any changes made to the ICR as a result of comments. In addition, the agency must enter the correct burden estimates.
  Inventory as of this Action Requested Previously Approved
11/30/2021 36 Months From Approved 11/30/2021
625,627,848 0 625,627,848
8,683,706 0 8,683,706
5,733,706 0 5,733,706

Part D plans and, to the extent applicable, MA organizations will use the information discussed below to comply with the eligibility and other requirements associated with their participation in Part D. CMS will use this information from plan sponsors and States to approve contract applications, monitor compliance with contract requirements, make proper payment to plans, and ensure that correct information is disclosed to potential and current enrollees. The new information collection will allow CMS to ensure sponsors have plans in place to restore business operations following a disruption of regular operations. Medicare beneficiaries will use the information provided by the Part D sponsors to make decisions regarding Part D enrollment as well as grievance and appeal requests. Under CMS-4182-P (RIN 0938-AT08), CMS will make the Preclusion List available to Part D sponsors. The Part D sponsors will perform system programming to maintain the Preclusion List in order to reject a pharmacy claim (or deny a beneficiary request for reimbursement) for a Part D drug that is prescribed by an individual on the Preclusion List. CMS will create and disseminate model notices to the prescribers to notify them of their existence on the Preclusion List, while the Part D sponsors will create and disseminate model notices to the Medicare beneficiaries to notify them that the pharmacy claim is being rejected or denied due to the prescriber’s existence on the Preclusion List.

Statute at Large: 18 Stat. 1860 Name of Statute: null
   PL: Pub.L. 108 - 173 101 Name of Law: Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)
  
PL: Pub.L. 108 - 173 101 Name of Law: Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)

0938-AT97 Proposed rulemaking 85 FR 9002 02/18/2020

  85 FR 9002 02/18/2020
No

7
IC Title Form No. Form Name
Business Continuity Plans under 422.504(o) and 423.505(p) CMS-10141, CMS-10141, CMS-10141, CMS-10141, CMS-10141, CMS-10141 Compensation Certification to be Completed by All Organizations ,   Compensation Structure for Plans ,   Covered Agent Information Sheet ,   Compensation Structure for Writing Agents by Contract/PBP Number ,   Compensation Certification to be Completed by Any Organization with Renewal Commission ,   Compensation Structure for Writing Agents
Medicare Prescription Drug Benefit Program (Benes)
Medicare Prescription Drug Benefit Program (Plans) CMS-10141, CMS-10141, CMS-10141, CMS-10141, CMS-10141, CMS-10141, CMS-10141, CMS-10141 Model Part D Explanation of Benefits ,   Exhibit A: Example Cover Page of the Model Part D EOB ,   Exhibit B: Examples of Section 1 (the List of Prescriptions) ,   Exhibit C: Example of Section 2 (Drug Payment Stages) ,   Exhibit D: Example of Section 3 (Amounts and Definitions for TrOOP and Total Drug Costs) ,   Exhibit E: Example of Section 4 (Changes to the Formulary) ,   Exhibit F: Example of Sections 5 and 6 (Information for Reference) ,   Exhibit G: Example of a Part D EOB (All Sections Included)
State Eligibility Determinations (423.904(b)) and Reporting (423.910(d))
System Programming (Plans) (section 423.120(c)(6))
Creation of Model Notices (Plans) (section 423.120(c)(6)) CMS-10141, CMS-10141, CMS-10141 Initial Notice Sent to Potentially At-Risk Beneficiaries ,   Second Notice Sent to Beneficiary Designating At-Risk Status ,   Alternate Second Notice Sent to Beneficiary Not Considered At-Risk
Preparation and Issuance of Model Notices (section 423.120(c)(6))

Yes
Miscellaneous Actions
No
This 2020 iteration proposes non-rule changes along with changes associated with a proposed rule (CMS-4190-P; RIN 0938-AT97) that published in the Federal Register on February 18, 2020 (85 FR 9002). See section 15 of the Supporting Statement for details.

$744
No
    No
    No
No
No
No
No
Mitch Bryman 410 786-5258 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
04/30/2020


© 2024 OMB.report | Privacy Policy